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Abstract
Study Objectives: To develop a patient-reported outcome measure to assess sleep amongst people experiencing problems with alcohol or 
other drugs.
Methods: Item development included secondary analyses of qualitative interviews with drug or alcohol users in residential treatment, a review 
of validated sleep measures, focus groups with drug or alcohol users in residential treatment, and feedback from drug or alcohol users recruited 
from community and residential settings. An initial version of the measure was completed by 549 current and former drug or alcohol users (442 in 
person and 107 online). Analyses comprised classical test theory methods, exploratory and confirmatory factor analysis, measurement invariance 
assessment, and item response theory (IRT).
Results: The initial measure (30 items) had good content and face validity and was named the Substance Use Sleep Scale (SUSS) by addiction 
service users. After seven items were removed due to low item-factor loadings, two factors were retained and labeled: “Mind and Body Sleep 
Problems” (14 items) and “Substance-Related Sleep Problems” (nine items). Measurement invariance was confirmed with respect to gender, 
age, and administration format. IRT (information) and classical test theory (internal consistency and stability) indicated measure reliability. 
Standard parametric and nonparametric techniques supported convergent and discriminant validity.
Conclusions: SUSS is an easy-to-complete patient–reported outcome measure of sleep for people with drug or alcohol problems. It can 
be used by those concerned about their own sleep, and by treatment providers and researchers seeking to better understand, assess, and 
potentially treat sleep difficulties amongst this population. Further validity testing with larger and more diverse samples is now required.
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Statement of Significance
The Substance Use Sleep Scale (SUSS) is the first sleep measure designed specifically for people experiencing problems with alcohol or 
other drugs. It comprises 23 items and two factors: “Mind and Body Sleep Problems” and “Substance-Related Sleep Problems.” SUSS was 
developed with significant input from substance users and can be used by them to monitor and reflect on their own sleep; by treatment 
providers to encourage and enable people who use substances to think about sleep and identify strategies for improving sleep; and 
by researchers and others as an outcome measure when designing and implementing sleep interventions for this population. Further 
validity testing, involving larger and more diverse samples, is now needed.
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Introduction
In a comprehensive review of the biomedical literature on sleep 
and substance use disorders, Arnedt et al. report that “nearly all 
substances ingested prior to bedtime alter the subjective and 
objective experience of sleep” (p.527) [1]. For example, the acute 
administration of drugs in the opioid class can increase noctur-
nal arousals and stage shifts, decrease total sleep time and sleep 
efficiency, and reduce the time spent in rapid eye movement 
(REM) sleep. Alcohol suppresses REM sleep in healthy individu-
als and is associated with short sleep duration in people who 
are alcohol dependent. Additionally, people experiencing sleep-
ing difficulties often consume drugs or alcohol to help them fall 
asleep—thus indicating that sleep problems are a risk factor for 
substance misuse [1].
The sociological literature on sleep and substance use dis-
orders is less well developed than the biomedical literature, 
although complex interactions between sleep, substance use, 
treatment, and recovery processes have been reported. In one 
qualitative study of current and former heroin users, partici-
pants repeatedly complained that sleeping problems caused 
them to feel distressed, exhausted, and unable to cope [2, 3]. 
Sleep tended to worsen during periods of detoxing, with indi-
viduals reporting difficulty falling asleep, waking through-
out the night, waking early in the morning, having “restless,” 
“jumpy,” and “twitchy” legs, and vivid dreaming (including 
nightmares and disturbing dreams with drug-using content). 
Difficulties sleeping and tiredness constrained their capacity to 
participate in therapeutic activities when in treatment, had the 
potential to trigger relapse, and generally undermined recov-
ery efforts [2, 3].
In another qualitative study (comprising focus groups with 
people reporting a drink or drug problem, being treated in resi-
dential detoxification or rehabilitation, or defining themselves 
as abstinent), “sleeping well” was consistently identified as an 
important indicator of recovery from addiction [4]. This finding 
supported the earlier study of current and former heroin users 
in which individuals who were attempting to reduce or abstain 
from heroin use described how they tried hard to establish more 
regular sleeping patterns, explained that they often found the 
structured bedtime routines of residential drug treatment help-
ful, and expressed relief and satisfaction when sleep patterns 
started to improve [3].
Within the general population, the relationship between 
sleep and health (physical and mental) has been widely docu-
mented [5, 6]. Sleep deficiency is associated with anxiety and 
depression, weight gain, impaired immune response, and 
increased risk of numerous diseases [5–11]. Tiredness decreases 
motor and cognitive performance, reducing communication and 
decision-making, impairing memory and concentration, and 
increasing the risk of accidents and injuries [5, 6, 12, 13]. Sleep 
duration has also been linked to all-cause mortality in a num-
ber of populations [5, 6, 14, 15]. Given the importance of sleep to 
health, scientists and clinicians have developed ways of evalu-
ating sleep and sleep-related impairments [5]. These include 
functional imaging and electrophysiological techniques and 
actigraphy. However, the most practical and widely used tools 
for evaluating sleep are self-report instruments, for example, 
sleep diaries, but also questionnaires that have been validated 
to assess particular types of sleep disturbance or to characterize 
symptoms of particular sleep disorders [5].
Although validated sleep measures have been used in a 
number of studies of people addicted to alcohol or other drugs 
[16–22], there is currently no sleep measure developed explic-
itly for people experiencing substance dependence. This is a 
limitation given that individuals who report problems with 
alcohol or other drugs may experience particular constella-
tions of sleep-related difficulties, which change depending 
on the substances taken, whether an individual is detoxing 
or not, and whether an individual has sleep routines imposed 
on them (e.g. in residential treatment or prison). The lack of 
a specific standardized, validated questionnaire makes it dif-
ficult for those experiencing substance-related impaired sleep 
to convey the nature and strength of their sleep problems. It 
also poses challenges for those seeking to better understand, 
assess, and potentially treat sleep difficulties amongst alcohol 
and other drug users.
Self-completion questionnaires that assess subjective 
health status are often referred to as patient-reported outcome 
measures (PROMs) [23]. PROMs are used across many areas of 
medicine, but have received comparatively less attention from 
within the drug and alcohol sector, perhaps reflecting the fact 
that historically alcohol and other drug users have not tended to 
be widely consulted by treatment providers or scale developers. 
Although the methodology for developing PROMs is constantly 
evolving, it is generally agreed that individuals from the target 
patient population should be involved in item and scale devel-
opment. This helps us to ensure that the constructs measured 
and the language and terminology used are acceptable to, and 
reflect the priorities and preferences of, those who will later 
complete the measure [4, 24, 25]. Once developed, PROMs should 
be subjected to rigorous psychometric testing [23].
The aim of our study was to develop a new PROM to assess 
sleep amongst people experiencing problems with alcohol or 
other drugs. The work was undertaken in two phases. Phase 1 
identified items for the new PROM (ensuring good face and con-
tent validity, acceptability, and usability for the target popula-
tion). Phase 2 then evaluated the psychometric properties and 
factorial structure of the new PROM. The study received ethical 
approval from a University Research Ethics Committee.
Methods
Phase 1 (hereafter, “item development”) occurred in three stages 
between July and October 2015. Data collection for phase 2 (here-
after, “measurement evaluation”) occurred in two subsequent 
stages between November 2015 and August 2016. To be eligible to 
participate in the study, individuals needed to (1) be over 18 years 
of age, (2) self-report current or previous problem substance 
use (illicit drugs or alcohol), (3) have sufficient understanding of 
English to be able to complete a basic questionnaire alone or with 
reading support, and (4) be able to give informed consent.
Support and advice were provided to the research team by 
two separate Project Advisory Groups (PAGs). The first PAG (PAG 
1)  comprised addiction service users, addiction clinicians and 
researchers, sleep clinicians and researchers, and a PROM expert 
(n = 10); it met once during November 2015. The second PAG (PAG 
2)  comprised addiction service users only (n  =  11); this group 
met several times throughout the study and also provided ad 
hoc advice on a small group and individual basis by telephone, 
email, and in person (IP) as issues needing discussion arose. 
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Service user advisors were each paid £20 per consultation; other 
advisors were not paid.
Item development
Stage 1: Identifying candidate items
Stage 1 involved secondary analyses of a pre-existing qualitative 
data set generated during a separate but linked study of sleep 
and addiction in residential rehabilitation settings [26, 27]. This 
prior study had been undertaken in residential treatment ser-
vices in England during 2014 and 2015. Semi-structured inter-
views had been conducted with 19 women and 9 men (n = 28). 
Their ages had ranged from 24 to 83 years, and they had self-
reported a mixture of alcohol, illicit drug, and prescription drug 
misuse. For the present study, the transcribed interview data 
were reanalyzed to identify sleep-related themes that might 
constitute candidate items for the new PROM.
In addition, the research team separately reviewed twelve vali-
dated sleep measures that had all previously been used in studies 
of people addicted to drugs or alcohol (Supplementary Table S1). 
Items that complemented or supported the themes discussed in 
the 28 qualitative interviews were added to the list of candidate 
PROM items. The list was then screened by four addiction service 
users (2 men and 2 women) from PAG 2. The four PAG 2 members 
were asked to suggest additional items, reword items, or remove 
irrelevant items. They were also consulted on the most appropri-
ate time scale and scoring system for the new PROM.
Stage 2: Creating a draft measure
In stage 2, all the candidate items identified in stage 1 were dis-
cussed within two focus groups of treatment clients. Focus group 
participants were recruited from two residential services, both 
of which provided detoxification and structured support (neither 
service had been involved in stage 1). Participants included 9 
men and 3 women (n = 12), their ages ranged from 27 to 47 years, 
and they reported misuse of alcohol, illicit drugs, and prescribed 
drugs (often in combination). Each focus group participant 
received a £15 shopping voucher in compensation for their time.
The focus group participants were invited to debate the long 
list of candidate items from stage 1, add new items, suggest any 
changes to wording, or remove any items. Feedback from the 
focus groups was discussed with members of PAG 2 on two sep-
arate occasions and the long list of items was revised according 
to their advice. Following this, a draft sleep PROM was prepared 
by the research team.
Stage 3: Assessment of face and content validity, acceptability, 
and usability
In stage 3, a new sample of 30 current and former drug and alco-
hol users completed the draft PROM in person, commenting on 
the content, time scale, wording, scoring system, and layout. 
Participants were recruited through a variety of community set-
tings (n = 22), residential settings (n = 4), and an outreach setting 
for people sleeping on the streets (n = 4). They included 26 men 
and 4 women; age range = 29–65 years. In total, 27 had used drugs 
or alcohol in the last 6 months. Of these, 10 reported that their 
main substance was an illicit drug, 8 reported that their main 
substance was alcohol, and 9 reported that they used illicit drugs 
and alcohol equally. All participants received a £15 voucher in 
compensation for their time. The research team used the par-
ticipants’ feedback to modify the draft sleep measure, and the 
modified version was then discussed with PAG 1 members.
Measurement evaluation
Stage 4: In Person (IP) sample
For stage 4, we recruited current and recent drug and alcohol 
users (n = 442) from community treatment services, homeless 
hostels, and peer support services across five English towns and 
cities. These individuals completed a questionnaire that com-
prised basic demographic, drug use and sleep questions, and 
the draft sleep measure. To maximize recruitment and comple-
tion, the questionnaire was kept as short as possible so that it 
could be answered relatively quickly (< 15 min), even by people 
who might have limited literacy or find it difficult to concentrate 
due to drug or alcohol withdrawal symptoms. Participants were 
offered refreshments to compensate for their time.
In order to conduct more advanced validation work, add-
itional data (including some follow-up data) were required. As we 
were concerned about the burden, this would place on our target 
population, and also the difficulty of tracking and relocating par-
ticipants across many locations simultaneously, we only collected 
these additional data from a subsample of participants attending 
services in one city. We recruited to preset targets that we believed 
would be both feasible and adequate for the analyses and front-
ended the data collection to ensure that our targets were met. 
Accordingly, the first 100 participants also completed two validated 
measures: (1) the Pittsburgh Sleep Quality Index (PSQI) [28] and (2) 
the Substance Use Recovery Evaluator (SURE) [29]. The PSQI is a 
self-rated questionnaire which assesses sleep quality and distur-
bances over a 1 month time interval, score range 0–21 where lower 
scores denote better sleep quality. SURE is a psychometrically valid 
PROM for recovery from drug and alcohol dependence, score range 
21–63 where higher scores denote greater recovery. Of these 100 
individuals, the first 42 completed the questionnaire and vali-
dated measures a second time, 2–5 days later. These 42 individuals 
received a £10 supermarket voucher for each questionnaire com-
pleted. Of these 42 individuals, 22 also wore actigraphs for a period 
of 7 days. These 22 participants received a further £10 voucher for 
the inconvenience of wearing the watches.
Stage 5: Online (OL) sample
To expand the geographical reach of the data collection and to 
ensure that we recruited beyond current treatment populations, 
an online (OL) version of the demographic, drug use and sleep 
questions and the sleep measure was created using the survey 
tool BOS (https://www.onlinesurveys.ac.uk/). The OL survey was 
open to anyone who was currently in, or who had previously 
been in, community or residential treatment for an alcohol or 
other drug problem. The survey link was circulated to service 
user organisations and treatment services via social media 
(Twitter, LinkedIn) and email. No compensation was offered for 
completing the survey. In total, 107 individuals responded OL.
Statistical analysis
Actigraph data were entered into the software programme Sleep 
Analysis 7, and estimates of (1) sleep efficiency, (2) sleep latency, 
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(3) total sleep time, and (4) wake bouts for each participant 
were created. We used parametric (t test, Pearson’s correlation 
coefficient) and nonparametric methods (Mann–Whitney test, 
Spearman’s correlation coefficient) to test score differences and 
associations, subject to the symmetry of the distributions.
To assess the reliability of the new measure, both clas-
sical test theory (internal consistency and stability) and item 
response theory (IRT; information) approaches were used. 
Internal consistency was evaluated via Cronbach’s α coefficient 
[30], along with the item–total correlations and the computation 
of α if the item was omitted. Stability was evaluated via Cohen’s 
κ for each item [31], following Landis and Koch interpretations 
[32], along with the percentage of agreement. For the total scores 
(continuous variables), a (two-way mixed) intraclass correlation 
coefficient [33] was also calculated.
We performed item factor analysis (IFA) [34] suitable for bin-
ary items to identify the dimensionality of the measure. Both 
exploratory (EFA) and confirmatory (CFA) models were used, in 
different samples. Measurement bias (or violation of measure-
ment invariance) was evaluated via multiple groups of CFA for 
categorical exogenous variables (group membership) [35–37]. 
This was conducted in three stages. First, metric invariance was 
tested by restricting the loading of each item to its correspond-
ing factor to be equal across groups. Each item that demon-
strated metric invariance was equivalently related to its factor 
across groups. Second, scalar invariance was tested by restrict-
ing the thresholds of each item so that they were equal across 
groups. Each item that showed scalar invariance had the same 
probability of a positive response for individuals of the same 
trait level across groups. Third, strict invariance was tested by 
restricting the residual variances of each item so that they were 
equal across groups. Each item that demonstrated strict invari-
ance was explained similarly by their factor across groups. For 
continuous exogenous variables, such as age, measurement 
invariance was tested using the Multiple Indicators, Multiple 
Causes (MIMIC) model [38, 39]. A significant direct effect from 
the exogenous variable to a particular item demonstrated a lack 
of invariance, so raising concerns of measurement bias.
Classical test theory assesses the whole test as the unit of 
measurement, whereas IRT examines individual items or ques-
tions. IRT is a probabilistic model of the mathematical relation-
ship between individuals’ abilities (or other hypothesized traits) 
and the item characteristics. In other words, the probability 
that an individual will respond positively or correctly to an item 
designed to measure a particular trait is a function of the item’s 
difficulty, the item’s discrimination ability, and the amount of the 
underlying trait possessed by the individual. The two-parameter 
IRT model (2PL-IRT) [40] was used to evaluate the severity (dif-
ficulty), discrimination ability, and information (precision) of the 
items within each dimension of the final measure. Evidence of 
(concurrent) convergent and divergent validity was assessed 
via standard parametric and nonparametric techniques, as 
described above. The statistical software Mplus (version 7) was 
used for all latent trait models (IRT, IFA, EFA, CFA, and MIMIC).
The statistical software Mplus (version7) was used for all 
latent trait models (IRT, IFA, EFA, CFA, and MIMIC) and the fol-
lowing  goodness of fit measures are reported: the relative chi-
square (rel χ2: with preferred values close to 2; Hoelter [41]), the 
Root Mean Square Error of Approximation (RMSEA, with pre-
ferred values less than 0.8; Browne and Cudeck [42]), the Taylor–
Lewis Index (TLI, with preferred values higher than 0.9; Bentler 
and Bonett [43]), and the Comparative Fit Index (CFI, with pre-
ferred values higher than 0.9; Bentler [44]).
Results
Item development outcome
Stage 1: Identifying candidate items
Secondary analyses of the 28 qualitative interviews identi-
fied 72 themes for consideration as candidate PROM items 
(Supplementary Table  2). Following review of the 12 validated 
sleep measures, 21 new themes were added to the list of candi-
date items for the new sleep PROM (Supplementary Table 3). In 
consultation with the four PAG 2 members, the long list of candi-
date items was turned into 75 simple “no”/“yes” statements relat-
ing to sleep in the previous week (Supplementary Table 4). Binary 
response options were preferred over polytomous response 
options because they were considered easier for respondents 
to understand and complete. The last week was preferred over 
shorter and longer time frames as this was deemed long enough 
to capture sleep patterns without responses being undermined 
by poor recall. Supporting this, there is good evidence that other 
sleep-related PROMs, such as the PSQI and the Epworth Sleep 
Scale, can be administered with confidence for week-long report-
ing periods for between-subject analyses [45]. The expression 
“last week” was preferred to “last 7 days” since the word “days” 
could generate confusion amongst a population that has a ten-
dency to sleep during the daytime (rather than at night) when 
using substances but not when in treatment or abstinent [2, 3].
Stage 2: Creating a draft measure
Feedback from the focus group participants and PAG 2 mem-
bers indicated that some of the 75 sleep statements needed to 
be amended or removed. A key problem was that many focused 
on sleep “behaviors” rather than sleep “problems,” and these 
indicators of sleep behavior were not necessarily indicative of 
sleep problems. For example, discussions revealed that “sleep-
ing with the television or radio or music on” or “drinking a hot 
drink before bed,” or “napping during the day” could help some 
people to sleep, impede the sleep of others, and have no effect 
on yet others. Items considered ambiguous by the PAG were 
therefore removed.
The resultant draft PROM comprised 30 × “no”/“yes” state-
ments (scoring “0” and “1”; a higher score denoting more sleep 
problems). These statements focused on the previous week and 
related to seven broad aspects of sleep: “sleep satisfaction,” 
“sleep environment,” “falling asleep,” “night time activity,” “sleep 
quality,” “waking up,” and “daytime functioning” (Supplementary 
Table 5).
Stage 3: Assessment of face and content validity, acceptability, 
and usability
In the final development stage, 30 individuals completed the 
draft PROM. In response to a series of structured questions, all 30 
reported that the PROM was easy to understand, all 30 reported 
that it was easy to complete, 27 reported that the length was 
about right (two said it was too short and one said it was too 
long), and 20 reported that they had enjoyed completing it (10 
felt neutral and nobody actively disliked it). In total, 28/30 said 
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that there were no irrelevant questions and 28/30 thought the 
PROM covered everything necessary. Completion times ranged 
from 2 to 20 min (mean 9 min; with those taking longer often 
discussing their responses with the researcher because they 
seemed to be finding the questionnaire interesting). Following 
consultations with members of PAG 1, only a small number of 
minor wording changes were made, and good face and content 
validity, acceptability, and usability were confirmed. Members of 
PAG 2 named the measure the Substance Use Sleep Scale (SUSS).
Measurement evaluation outcome
Sample characteristics
Several differences between the demographic characteristics of 
the individuals who completed the measure IP and those who 
completed OL were evident (Table 1). The OL sample had higher 
percentages of women (63.6% vs 30.5%), individuals of white 
ethnicity (95.3% vs 78.7%), and individuals who left school after 
the age of 16 (77.6% vs 31.4%). Age did not differ significantly 
between the two samples, with the total sample being between 
20 and 71 years old. There were no differences with respect to 
length of problem substance use, and 9% of the total sample 
reported less than 10 years of drug or alcohol problems.
For the exploratory and confirmatory factor analysis, we 
used a random number algorithm (automatically generated by 
the software SPSS) to divide the IP sample (n  =  442) into two 
split halves (hereafter, IP-a and IP-b). Randomization produced 
two split halves that did not differ in terms of demographic or 
clinical characteristics. As the OL sample (n = 107) was too small 
to be similarly divided, it was instead used as a second confirm-
ation sample to strengthen the analyses.
Item selection
We began our analyses by testing for potential problematic items, 
using classical test theory tools. Grouping all items together, 
Cronbach’s α coefficient was 0.88 for the complete sample (IP: 
0.88; OL: 0.85). In the IP sample, there was no improvement in 
the reliability index by omitting items, and the item–total cor-
relations (biserial correlation coefficient r) varied between r = 0.3 
and r = 0.6. In the OL sample, there were some low item–total 
correlations (varying between 0.1 and 0.6), but no substantial 
reduction in α when items were omitted (Table 2). According to 
Landis and Koch [32], the level of agreement was fair to perfect 
(Cohen’s κ varied between 0.4 and 1). Agreement was higher 
than 73% in all cases, even for lower values of κ. Therefore, in 
terms of reliability (according to classical test theory assump-
tions), no problematic items were found and so all items were 
used in the EFA.
Exploratory IFA
All 30 items were included in an EFA model (sample IP-a). The 
sample correlation matrix produced seven eigenvalues larger 
than 1 (12.8, 3.1, 1.8, 1.6, 1.4, 1.1, 1.1). According to Kaiser’s crite-
rion, this suggested up to seven extracted factors. The scree plot, 
however, indicated a two-factor solution (Figure 1).
Table 3 presents the goodness of fit indices for all models, 
from the unidimensional solution to the seven-factor solution. 
Close fit was achieved at the two-factor solution. Increasing 
the number of factors to three or more resulted in nonsalient 
loadings, cross-loadings, and/or factors with a small number of 
items (and thus small reliability). All seven solutions were evalu-
ated in terms of the content of the extracted dimensions, and 
the two-factor solution was considered the most satisfactory in 
terms of face validity.
Three items (“disturbed by noise,” “disturbed by light,” and 
“woken up in the night and drunk caffeinated and/ or sugary 
drinks”) had loadings equal to or less than 0.3 on both factors, 
so they were omitted and the analysis was repeated. Four more 
items (“sleeping tablets or medicines to help me sleep,” “woken 
up short of breath,” “needed caffeine and/ or sugary foods or 
drink to get through the day,” “needed to sleep or to nap during 
the day”) were then also omitted since they had smaller loadings 
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Table 1. Descriptive indices by sample and in total
In person (N = 442) Online (N = 107) Total (N = 549)
N % N % N % Comparison
Age left school
≤16 years 301 68.1 24 22.4 325 59.2 χ2 = 18.568, df = 1, p < 0.001
>16 years 139 31.4 83 77.6 222 40.4
Ethnicity
White 348 78.7 102 95.3 450 82.0 χ2 = 16.049, df = 1, p < 0.001
Other 94 21.3 5 4.7 99 18.0
Gender
Female 135 30.5 68 63.6 203 37.0 χ2 = 40.277, df = 1, p < 0.001
Male 307 69.5 39 36.4 346 63.0
Mean (SD)
Median
(min–max) Mean (SD)
Median
 (min–max)
Mean
 (SD)
Median
 (min–max) Comparison
Age (years) 44.3 (9.8) 45 (20–69) 45.5 (9.7) 46 (22–71) 44.6 (9.8) 45 (20–71) t = 1.144, df = 545, p = 0.253
Duration of  
substance  
use (years)
20.1 (11.1) 20 (0–47) 19.9 (10.3) 20 (0–50) 20 (10.9) 20 (0–50) t = −0.212, df = 543, p = 0.833
PSQI score 9.8 (4.2) 9 (1–18)
SURE score 48.1 (9.7) 47 (26–63)
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compared with the rest of the items within their factor (<0.6 in 
all cases). This was undertaken as a stepwise procedure, omitting 
one item at the time (but only where omitting the item increased 
the content validity of the corresponding factors, as judged by the 
research team). The two-factor model was then refitted for the 
remaining items. The process stopped when (1) all items loaded 
at least 0.6, (2) the goodness of fit measures indicated a robust 
solution, and (3) team members confirmed that the content of 
each factor was adequately described by the items. The final 
solution had close fit to the data: rel χ2 = 1.66, RMSEA = 0.055 with 
95% CI: (0.04, 0.07), CFI = 0.95, and TLI = 0.94. The corresponding 
EFA loadings, under OBLIMIN rotation, are presented in Table 4.
Confirmatory IFA
The two-factor (23-item) solution also had a close fit to the 
IP-b data: rel χ2 = 1.82, RMSEA = 0.061 with 95% CI: (0.05, 0.07), 
CFI = 0.94, and TLI = 0.94. Additionally, the values of the goodness 
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Table 2. Reliability: internal consistency indices by sample and test–retest agreement
Statement
IP sample (N = 442) OL sample (N = 107) Test–retest (N = 42)
Corrected 
item–total 
correlation
Cronbach’s α if 
item deleted
Corrected 
item–total 
correlation
Cronbach’s 
α if item 
deleted Cohen’s κ (95% CI)
% of  
agreement
Wanted to sleep better 0.45 0.88 0.61 0.84 0.4 (0.0, 0.7) 78.6
Worried about my sleeping 0.48 0.88 0.52 0.84 0.6 (0.4, 0.9) 81.0
Woken up tired most 
mornings
0.49 0.88 0.54 0.84 0.8 (0.6, 1.0) 92.9
Disturbed by noise 0.31 0.88 0.26 0.85 0.6 (0.3, 0.8) 78.6
Disturbed by light 0.31 0.88 0.23 0.85 0.5 (0.2, 0.9) 85.7
Felt too unsafe to sleep 0.36 0.88 0.41 0.84 0.4 (0.0, 0.9) 90.5
Difficulty falling asleep 0.55 0.88 0.44 0.84 0.9 (0.7, 1.0) 92.9
Uncontrollable/racing 
thoughts when I tried to 
sleep
0.56 0.88 0.54 0.84 0.8 (0.6, 1.0) 90.5
Negative emotions when 
I tried to sleep
0.57 0.88 0.53 0.84 0.8 (0.6, 1.0) 88.1
Sleeping tablets or medicines 
to help me sleep
0.35 0.88 0.14 0.85 0.8 (0.6, 1.0) 90.5
Drunk alcohol to help me 
sleep
0.41 0.88 0.40 0.84 0.8 (0.6, 1.0) 95.2
Street drugs to help me sleep 0.40 0.88 0.16 0.85 0.7 (0.4, 1.0) 90.5
Waking up lots in the night 0.43 0.88 0.39 0.84 0.8 (0.6, 1.0) 90.5
Woken up in the night and 
drunk caffeinated and/or 
sugary drinks
0.21 0.88 0.17 0.85 0.7 (0.4, 0.9) 88.1
Woken up in the night and 
drunk alcohol
0.37 0.88 0.30 0.85 0.9 (0.7, 1.0) 97.6
Woken up in the night and 
used street drugs
0.41 0.88 0.31 0.85 0.5 (0.0, 0.9) 90.5
Woken up in the night and 
smoked tobacco
0.40 0.88 0.37 0.84 1.0 (0.9, 1.0) 97.6
Panic attacks in the night 0.46 0.88 0.29 0.85 0.6 (0.3, 0.9) 88.1
Vomited in my sleep 0.26 0.88 - - 1 100
Dreams which disturbed sleep 0.42 0.88 0.35 0.84 0.6 (0.3, 0.8) 81.0
Aches and pains that stopped 
me from sleeping
0.45 0.88 0.44 0.84 0.6 (0.4, 0.9) 81.0
Felt restless in my sleep 0.53 0.88 0.49 0.84 0.7 (0.4, 0.9) 83.3
Woken up feeling confused or 
disoriented
0.49 0.88 0.34 0.85 0.7 (0.4, 0.9) 85.7
Woken up with a hangover or 
drunk
0.41 0.88 0.39 0.84 0.7 (0.4, 1.0) 95.2
Woken up withdrawing 0.42 0.88 0.43 0.84 0.7 (0.4, 1.0) 90.5
Needed alcohol or drugs to get 
out of bed
0.46 0.88 0.31 0.85 0.4 (0.0, 0.8) 88.1
Woken up short of breath 0.46 0.88 0.24 0.85 0.5 (0.2, 0.9) 85.7
Too tired to think clearly or to 
do things during the day
0.58 0.88 0.53 0.84 0.5 (0.2, 0.7) 73.8
Needed caffeine and/ or sug-
ary foods or drink to get 
through the day
0.31 0.88 0.29 0.85 0.7 (0.5, 0.9) 85.7
Needed to sleep or to nap dur-
ing the day
0.35 0.88 0.32 0.85 0.8 (0.5, 1.0) 88.1
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of fit indices and the loadings resembled those in EFA (Table 4). 
CFA was next applied to the OL sample data, revealing a close fit 
(rel χ2 = 1.31, RMSEA = 0.054 with 95% CI: (0.03, 0.07), CFI = 0.92, 
and TLI = 0.92) and large loadings.
The two factors were named based on the content of their 
items, with factor 1 referred to hereafter as “Mind and Body 
Sleep Problems” (MBSP) and the second factor referred to as 
“Substance-Related Sleep Problems” (SRSP).
Measurement invariance
The next stage of our analysis involved testing for potential 
measurement bias in relation to how the data were collected 
(IP or OL), age, and gender. For this, the two random split halves 
were combined and the total IP sample was used.
Invariance in IP and OL samples
Metric invariance held between the OL and IP samples (DIFFTEST: 
χ2 = 30.51, df  = 20, p  = 0.06). Full scalar invariance did not hold 
(DIFFTEST: χ2 = 54.83, df = 20, p < 0.001) and the modification indi-
ces suggested that the fit of the model could be improved by 
allowing the thresholds of the items “drunk alcohol to help me 
sleep” and “woken up with a hangover or drunk” to vary. By allow-
ing this, partial scalar invariance was held (DIFFTEST: χ2 = 22.42, 
df = 18, p = 0.214). When evaluating the residual variances, strict 
invariance also held (DIFFTEST: χ2 = 30.68, df = 22, p = 0.103).
All items related to their factor (MBSP or SRSP) similarly 
across the IP and OL samples (metric invariance). For 21/23 
items, individuals who completed the questionnaire IP had 
the same expected response as individuals who completed 
the questionnaire OL, when they had the same levels of MBSP 
and SRSP (partial scalar invariance). However, for the same lev-
els of SRSP, the IP sample had a greater probability of reporting 
“drinking alcohol to help sleep” (threshold: IP = 0.68, OL = −0.45) 
and a greater probability of reporting “waking up with a hango-
ver” (threshold: IP = 1.1, OL = −0.32). The amount of item vari-
ance explained by each factor was the same across the IP and 
OL samples for all items (strict invariance).
As there was full invariance with respect to loadings and 
residuals and 91% invariance with respect to the thresholds, we 
concluded that there was no substantial measurement bias, and 
the IP and OL samples were merged for the remaining analyses.
Invariance with respect to gender and age
When the IP and OL data were combined for the gender and age 
invariance tests, full measurement invariance held with respect 
to gender (Metric DIFFTEST: χ2 = 19.72, df = 21, p = 0.539; Scalar 
DIFFTEST: χ2 = 29.75, df = 21, p = 0.097; Strict DIFFTEST: χ2 = 21.74, 
df = 23, p = 0.536).
We then used the MIMIC model to detect direct effects 
of age (measured on a continuous scale) on individual items. 
Assuming the same levels of MBSP, increasing age was associ-
ated with reduced probability of people reporting both “dif-
ficulty falling asleep” (d.e.  =  −0.025, p  =  0.001) and “negative 
emotions when trying to sleep” (d.e. = −0.023, p = 0.004). In con-
trast, for the same levels of MBSP, increasing age was associ-
ated with increased probability of people reporting “aches and 
pains that stopped sleeping” (d.e. = 0.044, p < 0.001). For the same 
levels of SRSP, the probability of reporting “drinking alcohol to 
help sleep” (d.e. = 0.024, p = 0.018) and “waking up in the night 
and drinking alcohol” (d.e.  =  0.044, p  <  0.001) both increased 
with age. However, the magnitude of the direct effects was very 
small and our results therefore indicated that age did not bias 
measurement.
Item response theory
IRT was performed separately on each factor to evaluate the 
severity (difficulty), discrimination ability, and information 
(precision) of each item separately. Given the lack of substan-
tial measurement invariance, we used the complete sample for 
these analyses (n = 548). Figure 2 depicts the item characteris-
tic curves (ICC, for the severity and discrimination ability of the 
items) and the information curves (IFC, for the level of preci-
sion provided by the items) for each item within its factor. The 
severity and discrimination parameters are presented in Table 5 
and the item and test information for each factor is shown in 
Supplementary Table 6.
Mind and body sleep problems
In terms of MBSP, “wanting to sleep better” was the least severe 
item and it was more likely to be reported by people with less 
than average MBSP scores. The most severe item was “felt too 
unsafe to sleep,” which was more likely to be reported by indi-
viduals with above average MBSP scores. The MBSP items best 
able to discriminate between individuals with different sever-
ity of MBSP were “uncontrollable/racing thoughts when I  tried 
to sleep” and “negative emotions when I  tried to sleep.” Thus, 
reporting or not reporting one of these two problems made the 
largest difference in the expected quality of sleep. These two 
items were also the most informative (precise) for individuals 
with average sleep quality ± 1 standard deviation (SD). For indi-
viduals with higher levels of MBSP, “felt too unsafe to sleep” and 
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Figure 1. Scree plot (sample OL-a).
Table 3. Goodness of fit indices—EFA-sample IP-a (N = 221)
# of factors Rel χ2 RMSEA CFI TLI
One 2.1 0.071 0.89 0.88
Two 1.4 0.042 0.96 0.96
Three 1.2 0.032 0.98 0.98
Four 1.1 0.026 0.99 0.99
Five 1.1 0.015 >0.99 >0.99
Six 1.1 0.013 >0.99 >0.99
Seven 1.1 0.004 >0.99 >0.99
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“experiencing panic attacks in the night” were the most inform-
ative items. For individuals with lower levels of MBSP, “wanting 
to sleep better” and “woken up tired most mornings” were the 
most informative.
The IFCs indicated that the MBSP items could measure 
problems precisely across the MBSP continuum; indeed, both 
the ICCs and the IFCs were spread across the MBSP latent con-
tinuum (Figure 2).
Substance-related sleep problems
Turning to SRSP, “vomited in my sleep” was the most severe item 
and “woken up in the night and smoked tobacco” was the least 
severe. “Woken up in the night and drunk alcohol,” “woken up in 
the night and used street drugs,” and “needed alcohol or drugs 
to get out of bed” were the most discriminative, although most 
items performed similarly well. For individuals with up to average 
SRSP, “needing alcohol or drugs to get out of bed” was the most 
informative item. For higher levels of SRSP, most IFCs peaked at 
about 1 SD above average. That is, the precision of the items was 
maximized for individuals with SRSP scores close to 1 SD above 
average. “Vomiting in my sleep” had low precision for individuals 
with low to up to 1 SD above average SRSP levels. However, for 
high SRSP levels, “vomited in my sleep” was the most informa-
tive item; indicating that this question was particularly useful for 
identifying individuals with severe substance-related problems.
Whilst the ICCs of MBSP were spread over the latent con-
tinuum (± 2 SD from the mean), the characteristic curves of 
the SRSP items were located at above average sleep problems. 
This indicated that SRSP items pertained largely to very poor 
quality sleep.
Reliability and validity
Reliability
Reliability tests on the final 23-item sleep PROM showed that 
Cronbach’s α coefficient was still 0.88 for the complete sample, 
with no improvement in the reliability index gained by omit-
ting items. The item–total correlations varied between r  =  0.3 
and r = 0.6. For MBSP, α was 0.86 (item–item correlations: 0.2–0.6; 
item–total correlations: 0.4–0.6) and no problematic items were 
found. For SRSP, which comprised a smaller number of items, 
α was 0.79 (item–item correlations: 0.14–0.7; item–total cor-
relations: 0.3–0.6) and no problematic items were found. Thus, 
internal consistency was granted for the final measure in the 
complete sample.
With respect to the stability of the final measure, all items 
had fair-to-perfect agreement as reported previously (Table  2; 
Cohen’s κ varied between 0.4 and 1) [32]. With respect to the fac-
tor and total scores, the intraclass correlation coefficient indi-
cated almost perfect agreement between the two time points in 
all cases (MBSP: 0.96, 95% CI: [0.92, 0.98]; SRSP: 0.97, 95% CI: [0.95, 
0.99], TS: 0.96, 95% CI: [0.92, 0.98]). We therefore concluded that 
the measure was reliable, both according to classical test theory 
(internal consistency, stability) and IRT.
Validity
In terms of validity, the new measure correlated moderately to 
strongly with the PSQI and SURE scores demonstrating conver-
gent validity. In contrast, there were only low or nonsignificant 
correlations with actigraphy scores indicating discriminant 
validity (Table 6).
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Table 4. EFA and CFA loadings per sample—final model
Sample
IP-a(EFA) IP-b(CFA) OL(CFA)
Item Description MBSP SRSP MBSP SRSP MBSP SRSP
I06 Uncontrollable/racing thoughts when I tried to sleep 0.9 0.0 1.0 1.0
I07 Negative emotions when I tried to sleep 0.9 −0.1 1.1 1.0
I02 Worried about my sleeping 0.8 −0.1 0.9 0.9
I01 Wanted to sleep better 0.9 −0.1 0.9 1.1
I05 Difficulty falling asleep 0.8 0.0 0.9 0.9
I14 Panic attacks in the night 0.6 0.1 0.8 0.7
I03 Woken up tired most mornings 0.7 0.1 0.8 1.0
I10 Waking up lots in the night 0.6 0.0 0.7 0.8
I19 Woken up feeling confused or disoriented 0.7 0.1 0.8 0.7
I18 Felt restless in my sleep 0.7 0.2 0.8 0.9
I04 Felt too unsafe to sleep 0.6 0.0 0.7 1.0
I23 Too tired to think clearly or to do things during the day 0.6 0.3 0.8 1.0
I16 Dreams which disturbed sleep 0.7 0.0 0.7 0.6
I17 Aches and pains that stopped me from sleeping 0.6 0.1 0.7 0.8
I12 Woken up in the night and used street drugs 0.0 0.9 1.0 1.0
I09 Street drugs to help me sleep −0.1 0.9 1.0 0.7
I11 Woken up in the night and drunk alcohol −0.1 0.9 0.8 0.8
I08 Drunk alcohol to help me sleep 0.1 0.7 0.9 1.0
I20 Woken up with a hangover or drunk 0.2 0.6 0.9 1.1
I22 Needed alcohol or drugs to get out of bed 0.1 0.7 0.9 1.0
I15 Vomited in my sleep* 0.2 0.6 0.6 -
I13 Woken up in the night and smoked tobacco 0.2 0.5 0.6 0.7
I21 Woken up withdrawing 0.2 0.6 0.7 1.1
All loadings marked with bold were significant. EFA loadings according to OBLIMIN rotation. In the OL sample, item I15 “vomited in my sleep” was omitted because 
there were no positive responses.
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The new measure was also able to discriminate between 
subgroups of substance users (Table  7). For example, people 
who reported insomnia had significantly higher factor scores 
than those who did not report insomnia (both factors); people 
who had been homeless in the last month scored significantly 
higher than those who had not been homeless in the last month 
(both factors); and people who had been in paid work in the last 
month scored significantly lower than those who had not been 
in paid work in the last month (both factors).
Analyses presented in Table 7 also provide further evidence 
that the two factors are distinct in terms of content. Thus, people 
who reported mental health problems had significantly higher 
MBSP scores than those who did not report mental health prob-
lems, but the two groups did not have significantly different 
SRSP scores. Meanwhile, gender and education were not related 
to MBSP, but were related to SRSP.
Discussion
Sleep is an important, but frequently overlooked, issue for peo-
ple addicted to alcohol and other drugs. Although there are 
many validated sleep measures, none has been developed spe-
cifically for people experiencing problems with substances and, 
consequently, there has been no reliable way of assessing the 
self-reported sleep problems of this population. We completed 
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Figure 2. Item characteristic curves (ICC) and item information curves (IFC) for each factor.
Table 5. IRT parameters (p < 0.05 in all cases)
Item Discrimination Difficulty
MBSP I01 1.98 −1.10
I02 1.82 −0.33
I03 1.80 −0.87
I04 1.51 1.36
I05 2.14 −0.44
I06 2.89 −0.35
I07 2.74 −0.36
I14 1.70 0.91
I10 1.39 −0.59
I16 1.22 −0.59
I17 1.28 −0.05
I18 1.80 −0.31
I19 1.42 0.50
I23 1.71 −0.15
SRSP I08 1.87 0.63
I09 2.09 0.80
I11 2.27 1.14
I12 2.38 1.05
I13 1.32 −0.16
I15 2.00 2.20
I20 1.75 0.99
I21 1.63 0.74
I22 2.63 0.99
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extensive developmental work, comprising qualitative and quan-
titative methods, with significant input from people using drugs 
and alcohol in order to develop our new self-reported outcome 
measure of sleep problems. Members of our service user PAG con-
firmed face and content validity and determined the measure’s 
name: the SUSS. Statistical analyses established a two-factor 
structure, measurement invariance, reliability, and validity.
SUSS is shown in Table  8. It comprises 23 items and two 
factors: factor 1, “Mind and Body Sleep Problems” and factor 
2, “Substance Related Sleep Problems.” Each factor is intern-
ally coherent. Items score 0 or 1, so total scores range from 0 
to 23 (where lower scores denote better sleep and higher scores 
denote worse sleep). SUSS is worded so that it is accessible to 
people with limited literacy: it has a Flesch readability score 
(based on number of words per sentence and number of sylla-
bles per word) of 86.8 and a Lexile Measure (based on word fre-
quency and sentence length) of 400L–500L. These scores denote 
easy to read conversational English.
SUSS is quick and easy to complete (as little as 2  min). 
However, individuals frequently took longer to complete it 
because they chose to pause and reflect on individual items 
and to discuss their responses with the researcher. As has 
been argued previously [25, 29], a well-designed PROM will not 
simply generate numeric scores. It will also prompt people 
to reflect on and volunteer potentially important information 
about their lives and circumstances that might be helpful in 
a therapeutic context. Since only 1/30 people reported that 
the initial 30-item version of SUSS was too long (whereas 2/30 
reported it was too short), 20/30 reported that they enjoyed 
completing it, and 28/30 identified no irrelevant questions 
(Item development, stage 3), we do not feel that a short-
form version is an immediate priority for clinical practice. 
Nonetheless, we recognize that brevity is important when 
scales are used in studies alongside other assessments. IRT is 
not designed as a method to reduce the number of items in a 
measure, but our IRT parameters fully describe the function-
ality of each item and may thus facilitate item selection in the 
development of any future short form.
Factor 1 (“Mind and Body Sleep Problems”) comprises 14 
items that all relate to cognitive and behavioral difficulties and 
concerns about sleep. These include problems going to sleep 
(“uncontrollable/racing thoughts when trying to sleep,” “nega-
tive emotions when trying to sleep,” “difficulty falling asleep,” 
“feeling too unsafe to sleep,” “aches and pains that prevented 
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Table 6. Pearson correlation coefficients for the final 23-item sleep PROM
MBSP scores SRSP scores Total score
r P N r P N r P N
Age −0.1 0.001 547 −0.1 0.005 547 −0.2 <0.001 547
PSQI score 0.7 <0.001 100 0.3 0.001 100 0.7 <0.001 100
SURE score −0.5 <0.001 100 −0.6 <0.001 100 −0.6 <0.001 100
Actigraphy: Sleep efficiency −0.4 0.044 22 −0.3 0.197 22 −0.5 0.022 22
Actigraphy: Sleep latency 0.2 0.283 22 0.2 0.263 22 0.3 0.145 22
Actigraphy: Total sleep time −0.4 0.039 22 −0.1 0.569 22 −0.4 0.062 22
Actigraphy: Wake bouts 0.1 0.768 22 0.0 0.913 22 0.0 0.874 22
Table 7. Score differences in relation to demographic and clinical characteristics for the final 23-item sleep PROM
Factor
MBSP SRSP SP
95% CI Comparison 95% CI Comparison 95% CI Comparison
Gender
(Male–Female)
(−0.7, 0.6) t = −0.1, df−547, 
p = 0.922
(0.5, 1.3) W = 42915.5, p < 0.001 (0, 1.8) t = 1.9, df−547, 
p = 0.057
Ethnicity
(White–Other)
(−0.9, 0.8) t = 0, df−547,  
p = 0.962
(−0.9, 0.1) W = 19861, p = 0.086 (−1.6, 0.8) t = −0.7, df−547, p = 0.492
Education beyond 
16 years (N–Y)
(−0.2, 1.1) t = 1.4, df−545,  
p = 0.148
(0.8, 1.6) W = 46800, p < 0.001 (0.8, 2.6) t = 3.7, df−545, p < 0.001
Substance use in the 
last 6 months (Y–N)
(3.5, 1.9) t = 6.8, df−544,  
p < 0.001
(2.8, 1.9) W = 7583, p ≤ 0.001 (6.1, 4) t = 9.5, df−544, p < 0.001
Homeless in  
last month (Y–N)
(0.7, 2.6) t = 3.5, df−547,  
p < 0.001
(0.8, 1.9) W = 23805.5, p < 0.001 (1.7, 4.3) t = 4.7, df−547, p < 0.001
Had paid work in last 
month (Y–N)
(−1.9, −0.2) t = −2.4, df−547,  
p = 0.017
(−1.5, −0.4) W = 16065, p < 0.001 (−3.2, −0.8) t = −3.3, df−547, 
p = 0.001
Has a diagnosed  
physical health  
problem (Y–N)
(−0.4, 2.7) t = 1.5, df−98,  
p = 0.133
(−1, 0.9) W = 1204, p = 0.816 (−1, 3.1) t = 1.1, df−98, p = 0.293
Has a diagnosed  
mental health  
problem (Y–N)
(1.4, 4.3) t = 4, df−98,  
p < 0.001
(−0.5, 1.5) W = 1343, p = 0.235 (1.4, 5.4) t = 3.3, df−98, p = 0.001
Ever diagnosed  
insomnia (Y/N)
(1.8, 3.4) t = 6.4, df−522,  
p < 0.001
(−0.1, 0.9) W = 24339, p = 0.066 (1.9, 4.1) t = 5.4, df−522, p < 0.001
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sleeping”); problems staying asleep (“panic attacks in the night,” 
“waking up lots in the night,” “being restless during sleep,” 
“dreams that disturbed sleep”); and problems associated with 
fatigue on wakening and during the day (“waking up tired most 
mornings,” “waking up feeling confused and disoriented,” “being 
too tired to think clearly or do things during the day,” “wor-
rying about sleep,” “wanting to sleep better”). None of the 14 
items explicitly mentions drugs or alcohol and all items could 
be reported by individuals who do not consume substances. 
Nevertheless, the factor captures aspects of sleep (particularly, 
“racing thoughts,” “feeling unsafe,” “panic attacks,” “disturbing 
dreams,” and “waking up confused and disoriented”) that are 
germane to substance users [2, 3] and tend not to feature in 
other more generic sleep scales.
Items in Factor 2 (“Substance-Related Sleep Problems”) also 
relate to difficulties when trying to go to sleep, difficulties stay-
ing asleep, and difficulties on wakening. However, in contrast 
to factor 1, all factor 2 items (n = 9) refer directly or indirectly 
to substances (drugs, alcohol, or tobacco) and none would ever 
be reported by anyone who did not consume substances. Thus, 
five items explicitly mention drugs or alcohol (“waking up in the 
night and using street drugs,” “using street drugs to help sleep,” 
“waking up in the night and drinking alcohol,” “drinking alcohol 
to help sleep,” “needing alcohol or drugs to get out of bed”) and 
one item explicitly mentions tobacco (“waking up in the night 
and smoking tobacco”). The remaining three items (“woken up 
with a hangover,” “vomited in my sleep,” “woken up withdraw-
ing”) all clearly refer to the consequences of drug or alcohol con-
sumption and intoxication.
People experiencing problems with drugs and alcohol often 
report complex physical, psychological, and social problems 
that can impede sleep [3, 27]. Within the general population, 
biopsychosocial problems also undermine sleep [46]. We 
might therefore expect that people who report problematic 
substance use will experience at least some sleep difficulties 
independent of their alcohol and other drug consumption 
such that sleep problems will not simply disappear if they 
become abstinent. This assumption is supported by the two-
factor structure of SUSS which distinguishes more generalized 
MBSP from sleep problems related specifically to substance 
use. Reflecting this, we suggest that any interventions or strat-
egies designed to improve the sleep of people who use drugs 
or alcohol will need to address both their substance use and 
any wider biopsychosocial problems that patient and clients 
report; addressing substance use alone will likely generate 
only partial success [47].
Invariance testing revealed that participants who reported 
the same level of MBSP were less likely to report “difficulty fall-
ing asleep” and “negative emotions when they tried to sleep” 
but were more likely to report “aches and pains that stopped 
them from sleeping” as they aged. Meanwhile, participants with 
the same level of substance-related sleep problems were more 
likely to report “drinking alcohol to help them sleep” and “wak-
ing up in the night to drink alcohol” as they aged. These findings 
suggest that older people reporting problems with substances 
may experience sleep problems differently from younger peo-
ple. This may limit the ability of SUSS to measure and compare 
sleep problems across age groups. Nonetheless, the magnitude 
of the effects was low and changes to sleep patterns are part 
of the normal aging process. Studies have consistently shown 
a decrease in both sleep length and slow-wave sleep and an 
increase in sleep fragmentation in older adults [48, 49], as well 
as adaptation in perceptions of sleep and disturbances as we 
age [50]. Some basic differences in perceptions of sleep quality 
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Table 8. Substance Use Sleep Scale (SUSS)
Mind and body sleep problems—thinking about the last week No Yes
1. I have worried about my sleeping □ □
2. I have wanted to sleep better □ □
3. I have had difficulty falling asleep □ □
4. I have felt too unsafe to sleep □ □
5. I have had uncontrollable/racing thoughts when I tried to sleep □ □
6. I have had negative emotions (such as anger, guilt, or anxiety) when I tried to sleep □ □
7. I have had aches and pains that stopped me from sleeping □ □
8. I have been waking up lots in the night □ □
9. I have had panic attacks in the night □ □
10. I have had dreams which have disturbed my sleep □ □
11. I have felt restless in my sleep (e.g. jumpy, twitchy, or itchy legs) □ □
12. I have woken up feeling confused or disoriented □ □
13. I have woken up tired most mornings □ □
14. I have been too tired to think clearly or to do things during the day □ □
Substance-related sleep problems—thinking about the last week No Yes
15. I have drunk alcohol to help me sleep □ □
16. I have taken street drugs to help me sleep □ □
17. I have woken up in the night and drunk alcohol □ □
18. I have woken up in the night and used street drugs □ □
19. I have woken up in the night and smoked tobacco □ □
20. I have vomited in my sleep □ □
21. I have woken up with a hangover or drunk □ □
22. I have woken up withdrawing □ □
23. I have needed alcohol or drugs to get out of bed □ □
Items score 0 (No) or 1 (Yes), so total scores range from 0 to 23 (where lower scores denote better sleep and higher scores denote worse sleep).
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between age groups are therefore to be expected and do not not-
ably undermine the utility of SUSS.
The IRT models indicated that items relating to MBSP cap-
tured high, medium, and low levels of sleep difficulty, whereas 
items relating to SRSP mainly captured very poor sleep qual-
ity. Thus, people who have low SRSP scores (i.e. people who 
report that substance use is negatively affecting their sleep) 
are likely to have especially poor sleep. Addressing their sub-
stance use may significantly improve (although not necessar-
ily solve) their sleep problems. That the only item relating to 
tobacco “woken up and smoked tobacco” captured sleep qual-
ity at the higher end of substance-related sleep trait suggests 
that alcohol and other drug use are more closely associated 
with poor sleep than tobacco. Consequently, addressing alco-
hol and other drugs seems more likely to improve sleep than 
addressing smoking, although reduced use of tobacco should 
still improve sleep quality [51].
SUSS, the PSQI, and SURE are all self-report measures assess-
ing self-perceived health status, whereas actigraphy scores are a 
more objective measure of sleep based on movement. Given that 
subjective and actigraphic measurements of sleep are known to 
correlate poorly [52–54], our finding that SUSS correlated moder-
ately to strongly with the PSQI and SURE scores but not with the 
actigraphy scores are as anticipated. Similarly, we expected and 
found that SUSS correlated positively with two characteristics 
likely to be associated with poor sleep (insomnia and homeless-
ness) and negatively with one characteristic likely to be associ-
ated with good sleep (being in paid work). Meanwhile, gender 
and education were associated with SRSP but not MBSP, whereas 
having a diagnosed mental health problem was related to MBSP 
but not SRSP. These latter findings merit further consideration.
Although there is evidence of sex differences in sleep dif-
ficulties [55], analysis of large-scale survey data has suggested 
that a major reason why women self-report poorer sleep than 
men relates to women’s disadvantaged socioeconomic status 
[56]. Supporting this, Sekine et al. have found that gender differ-
ences in sleep could be entirely explained by gender differences 
in work characteristics, domestic roles, and family work con-
flicts [57]. The lack of association between gender and MBSP in 
our analyses may therefore relate to the specific socioeconomic 
patterns and dynamics of alcohol and other drug users. For 
example, poor education, low income, and unemployment tend 
to be high across both sexes, with some evidence that women 
may be better than men at managing the finances they do have 
once substance use stops [3, 58]. In terms of differences between 
mental health and the two sleep factors, there is a well-known 
association between poor mental health and the general sleep 
issues comprising factor 1 [59, 60]. There is, however, no current 
evidence of an association between mental health and the items 
comprising SRSP (factor 2).
Limitations and strengths
Self-report measures of sleep have limitations despite their 
widespread use [5]. Awareness is reduced during sleep and this 
limits the validity of sleep self-reports when assessing objective 
variables and phenomena such as snorting, apnea, or leg jerks 
[5]. Sleep can also vary considerably from day to day, meaning 
that multiple measures are often needed to derive stable meas-
ures [5]. Further validity testing of SUSS, based on larger and 
more diverse samples that would establish factor and total score 
norms and enable other group comparisons, is now needed. This 
might include people who consume alcohol or other drugs but 
do not consider that they have ever had a problem with sub-
stances; people from other patient populations who report sleep 
problems; and people from other countries and cultures where 
language, practices, and expectations relating to both sleep and 
substance use may vary. In addition, criterion and predictive val-
idity testing would be desirable.
In terms of its strengths, SUSS is the first sleep measure 
designed specifically for people experiencing problems with alco-
hol and other drugs. Moreover, people who used substances played 
a central role in establishing its content, and confirmed that it had 
good face validity. The measure was designed using a careful and 
considered blending of qualitative methods (with their focus on 
subjective meaning and understanding) and more objective quan-
titative techniques. This capitalized on the strengths of each to 
ensure a robust development and early validation process. Our 
study participants were diverse in terms of age, ethnicity, drugs 
used, and geographical location, so providing reassurances in terms 
of inclusion and diversity. That we successfully collected data OL 
suggests that a computer adaptive version can be designed. Lastly, 
SUSS seems likely to have a number of potentially important func-
tions. It might be used by people who use, or have used, substances 
to monitor and reflect on their own sleep; by treatment providers 
to encourage and enable people who use substances to think about 
their sleep and its diverse correlates, and to practice, evaluate, and 
deploy strategies for improving sleep; and by researchers and oth-
ers as an outcome measure when designing and implementing 
sleep interventions for this population.
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Supplementary material is available at SLEEP online.
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